EW Stock Analysis
NYQ · Healthcare · Medical Devices
$87.00
+0.71 (+0.82%)
EW Interactive Price Chart & Trading Signals
EW Stock Snapshot — Valuation, Risk & Technical Signals
EW Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$50.15B
P/E Ratio
51.79
Forward P/E
25.76
PEG Ratio
1.84
P/B Ratio
4.72
EPS
$1.68
Dividend Yield
—
52W Range
$72.30 – $96.29
Beta
0.85
Volume
0.8M
ROE
9.2%
Profit Margin
15.4%
Revenue Growth
13.6%
Gross Margin
77.8%
EV/EBITDA
23.18
Analyst Target
$100.96
The trailing price-to-earnings ratio stands at 51.8x. Forward P/E of 25.8x implies earnings expansion expected. Price-to-book is 4.72x. EV/EBITDA sits at 23.18x. Market capitalization is $50.15B. Revenue is growing at 13.6% on a trailing basis. Earnings are compressing at -25.4%. Profit margins are 15.4%. Return on equity is 9.2%. Beta of 0.85 indicates market-average volatility.
Analyst Consensus
Recommendation
Buy
Low Target
$84.00
Mean Target
$100.96
High Target
$110.00
Based on 26 analysts
About EW
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
EW Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
General investorWatch out for
Premium valuation, Earnings declineNon-zero inputs
4/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
Edwards Lifesciences Corporation (EW) trades above our multi-model fair value estimate of $27.34 by approximately 68.6%. Trailing P/E: 51.8x. Profitability signals include profit margin of 15.4% and return on equity of 9.2%. Recent growth metrics show revenue growth of 13.6% and earnings growth of -25.4%. Risk profile: beta of 0.85. Consensus: buy.
Valuation, Growth & Risk
Valuation
Overvalued
P/E 51.8x
Price is above what fundamentals suggest.
Growth
Expanding
Rev 13.6%
Revenue is outpacing the market.
Valuation Snapshot
Edwards Lifesciences Corporation (EW) trades above our multi-model fair value estimate of $27.34 by approximately 68.6%. The trailing price-to-earnings ratio stands at 51.8x. Forward P/E of 25.8x suggests earnings compression ahead. Price-to-sales is 7.7x. Price-to-book is 4.7x. EV/EBITDA sits at 23.2x. Market capitalization is $50.15B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 13.6% on a trailing basis. Earnings are compressing at -25.4%. Profit margins are 15.4%. Return on equity is 9.2%. Return on assets is 8.4%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 0.85 indicates market-average volatility. Net debt position is $-3548299904.00.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $100.96 implies 16.0% upside. Target range spans $84.00 to $110.00. 26 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
EW Overvalued
Edwards Lifesciences Corporation (EW) trades above our multi-model fair value estimate of $27.34 by approximately 68.6%.
Frequently Asked Questions
ValuationIs EW stock overvalued right now?
ValuationWhat is EW fair value based on current fundamentals?
RiskHow risky is EW compared with other stocks?
GrowthIs EW still growing?
AnalystWhat do analysts think about EW?
CatalystWhat could change the investment case for EW?
Related Stocks
About the Author
Phasakorn Traklang (Peach) — Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.